Science Explorer Back to mapMap
Discussion
Researcher · Mie University · Japan

Hiroaki Ikeda

Hiroaki Ikeda publishes mostly in Immunology, Oncology and Molecular Biology, on topics such as Immunotherapy and Immune Responses, CAR-T cell therapy research and Immune Cell Function and Interaction.

ORCID 0000-0002-8012-4796 OpenAlex
World rank
#1,934,215
of 7,710,434 ranked researchers
Rank in Japan
#34,575
of 383,136
Works
231
Citations
15k
Citations per work
63.1
h-index
42
i10-index 92Top 6.8% in Immunology
Hiroaki Ikeda

What does Hiroaki Ikeda research?

Hiroaki Ikeda's work is mostly in Immunology and Microbiology (23%), Medicine (22%), Biochemistry, Genetics and Molecular Biology (16%).

Everything else: 90 works · 39.1% of their workLife Sciences: 90 works · 39.0% of their workImmunology and Microbiology: 53 works · 22.9% of their workImmunology: 53 works · 22.9% of their workBiochemistry, Genetics and Molecular Biology: 37 works · 16.1% of their workMolecular Biology: 27 works · 11.8% of their workGenetics: 10 works · 4.3% of their workHealth Sciences: 51 works · 21.9% of their workMedicine: 51 works · 21.9% of their workOncology: 35 works · 15.1% of their workRadiology, Nuclear Medicine and Imaging: 8 works · 3.5% of their workSurgery: 8 works · 3.3% of their workTHEIR WORKHiroaki Ikeda231works
Life Sciences39%Health Sciences22%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
  1. Everything else9039.1%
    1. Immunology and Microbiology5322.9%
    2. Biochemistry, Genetics and Molecular Biology3716.1%
    1. Medicine5121.9%
  1. 1Immunology23% of their works
  2. 2Oncology15% of their works
  3. 3Molecular Biology12% of their works
  4. 4Genetics4% of their works
  5. 5Radiology, Nuclear Medicine and Imaging4% of their works
  6. 6Surgery3% of their works

Research topics

Which keywords describe Hiroaki Ikeda's research?

The keywords of their largest research topics: Cancer Immunotherapy, Dendritic Cells, Immunity, CAR T Cells, Chimeric Antigen Receptor, Natural Killer Cells, NK Cell Recognition and Immune Checkpoint Blockade.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Cancer Immunotherapy1242 topics
  2. Dendritic Cells721 topic
  3. Immunity721 topic
  4. CAR T Cells521 topic
  5. Chimeric Antigen Receptor521 topic
  6. NK Cell Recognition291 topic
  7. Natural Killer Cells291 topic
  8. Immune Checkpoint Blockade211 topic
  9. PD-1 and PD-L1211 topic
  10. Gene Therapy201 topic
  11. Viral Vectors201 topic
  12. Fc Receptors151 topic
  13. Foxp3151 topic
  14. TGF-ß151 topic
  15. Therapeutic Antibodies151 topic
  16. Glaucoma101 topic
  17. Intraocular Pressure101 topic

Where does Hiroaki Ikeda work?

Hiroaki Ikeda's main affiliation in the publication record is Mie University, Japan.

How many publications and citations does Hiroaki Ikeda have?

OpenAlex counts 231 works and 14,587 citations for Hiroaki Ikeda, an h-index of 42, ranking #1,934,215 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named Hiroaki Ikeda

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Hiroaki Ikeda. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.